Apollo 24|7 and the Shift Toward Digital Healthcare Discovery

Industry & Competitive Context

India’s healthcare delivery system has historically been built around physical infrastructure hospitals, standalone pharmacies, and in-person diagnostics in a market characterized by uneven access across urban and rural geographies. Over the past decade, this structure has been challenged by the emergence of digital health intermediaries. Online pharmacy and teleconsultation platforms such as Tata 1mg (formed through Tata Digital’s acquisition of 1mg), PharmEasy (which merged with Medlife and later consolidated under API Holdings), Netmeds (acquired by Reliance Retail in 2020), and Practo built businesses around medicine delivery, diagnostic test booking, and virtual doctor consultations, largely as asset-light, venture-funded entities without their own hospital networks.

Apollo Hospitals Enterprise Limited entered this contest from a different starting position. As one of India’s largest integrated healthcare providers, with a network of hospitals, pharmacies, and clinics built over decades, Apollo possessed physical assets doctors, diagnostic capacity, and a pharmacy retail footprint that pure-play digital entrants lacked. The strategic question the company faced was how to convert this physical scale into a digital-first channel for patient acquisition and engagement, rather than ceding the “digital front door” of healthcare the point at which a patient first searches for a doctor, orders a medicine, or books a test to asset-light competitors.

Brand Situation Prior to the Platform

Before the launch of Apollo 24|7, Apollo Hospitals’ digital presence was fragmented across hospital websites, a separate pharmacy ordering system, and limited telemedicine offerings. Patient interaction with the Apollo brand was largely transactional and location-bound: a person typically engaged with Apollo only once they had already decided to visit a specific hospital or pharmacy outlet. This meant the brand’s digital footprint did not fully capture the earlier stages of the patient journey symptom search, self-assessment, and provider discovery stages that competitors without physical infrastructure were already contesting online.

Apollo 24|7 was launched on February 5, 2020, as the company’s unified digital health platform, bringing online pharmacy ordering, virtual consultations, and diagnostic booking under a single app and web interface, ahead of the COVID-19 disruption that would soon reshape the entire category.

Strategic Objective

The stated objective behind Apollo 24|7, as communicated through company statements at the time, was to make Apollo’s clinical and pharmacy assets accessible digitally, “anytime, anywhere” the “24|7” naming convention itself signaling continuous access rather than the finite operating hours of a physical hospital or pharmacy outlet. The platform was positioned to extend Apollo’s reach beyond the physical catchment area of its hospitals and stores, using the company’s existing doctor network, pharmacy inventory, and diagnostic infrastructure as the backend for a consumer-facing digital interface. In effect, the objective was to reposition Apollo from a hospital chain that also had a website into a digital healthcare platform that happened to be backed by physical hospitals inverting the sequence in which patients were expected to encounter the brand.

Campaign Architecture & Execution

Apollo 24|7’s rollout unfolded in phases shaped significantly by external events. The app launched in early February 2020 with core functionality spanning online medicine ordering, consultation booking, and health content. Within weeks, India’s COVID-19 outbreak accelerated both demand for and investment in the platform. In March 2020, Apollo added a free, AI-based COVID-19 self-assessment chatbot, accessible through the app and as a standalone tool on the Apollo website, which asked users for age, gender, and symptoms before recommending whether to seek hospital care, undergo a scan, or stay home explicitly framed as a self-assessment aid rather than medical advice. This feature drove a documented surge in adoption: over 100,000 downloads were recorded within two days of its release, at a point when India had just over 467 confirmed COVID-19 cases and a 15-day period of social distancing had been ordered nationally.

In April 2020, Apollo extended the platform’s reach through a partnership with Bharti Airtel, embedding the AI-based COVID-19 risk assessment tool within the Airtel Thanks app, giving Apollo’s screening capability access to Airtel’s existing telecom subscriber base without requiring a separate app download a distribution tactic that borrowed reach from an unrelated but high-scale consumer platform rather than relying solely on organic or paid app-install campaigns.

The platform’s technical and functional buildout continued through 2020 and into 2021. On March 1, 2021, Apollo announced the nationwide scale-up of Apollo 24|7, built on Microsoft Azure infrastructure using Azure Database for PostgreSQL, Azure Kubernetes Service, and Azure DevOps for the underlying platform, with Azure Communication Services supporting chat, voice, video, and text-based interactions between patients and doctors. At the time of this announcement, the platform offered virtual consultations with doctors across more than 55 specialties, with a stated response benchmark of connecting patients to a certified doctor within 15 minutes; it drew on a network of over 7,000 doctors across Apollo’s hospitals and clinics, more than 4,000 pharmacy stores, and medicine delivery coverage extending to over 15,000 PIN codes, with two-hour delivery available in select cities. Beyond transactional services, the platform incorporated condition management tools, digital health records, a preventive health program branded Apollo ProHealth, a mental health self-assessment tool, and continued COVID-related features including a symptom scanner and post-COVID care guidance.

Subsequent architecture changes have been structural rather than purely marketing-led. In April 2024, Apollo HealthCo Limited the corporate entity housing Apollo 24|7 and Apollo’s pharmacy operations announced a merger with Keimed Private Limited, a wholesale pharmaceutical distributor, alongside an equity investment of Rs 2,475 crore (approximately $339 million) from Advent International, one of the world’s largest private equity investors, for a 12.1% stake in the merged entity. Under the announced structure, existing Apollo HealthCo shareholders retained 59.2% of the combined business, with Keimed shareholders holding up to 25.7%, and the combined enterprise was valued at approximately Rs 22,481 crore (roughly $3 billion), inclusive of Keimed’s own enterprise value of Rs 8,003 crore. This merger was intended to integrate Apollo’s digital front end more tightly with pharmaceutical distribution and supply chain, strengthening the backend that supports the app’s medicine delivery promise.

In June 2025, the Apollo Hospitals Enterprise board approved a plan to demerge its pharmacy and digital health businesses, including Apollo 24|7, into a separately listed entity named Apollo Healthtech Limited. This restructuring received clearance from the Competition Commission of India in September 2025, and the company has targeted a listing of the new entity around the fourth quarter of fiscal year 2027, with projected combined digital and pharmacy revenue guidance of approximately Rs 25,000 crore by FY27 at margins of around 7%, as indicated in company disclosures.

Positioning & Consumer Insight

Apollo 24|7’s positioning rests on a specific interpretation of consumer behavior in Indian healthcare: that trust in a digital health platform is built not on the interface alone, but on the credibility of the clinical network and supply chain behind it. Unlike pure-play digital entrants that had to build clinical credibility from a standing start, Apollo’s positioning leveraged decades of hospital-brand trust, repackaging it for a digital-first interaction model. The “24|7” framing directly addresses a consumer insight around the inconvenience and unpredictability of acute health needs illness does not respect business hours, and a platform promising round-the-clock access to consultation, medicine, and diagnostics speaks to a felt gap in traditional healthcare access, particularly outside large metro centers.

The COVID-19 period sharpened this positioning further: the self-assessment chatbot and later features were not simply engagement tools but responses to an acute, widely shared anxiety uncertainty about whether a given symptom warranted hospital care during a period when hospitals themselves were viewed as high-risk environments. By offering a free, low-friction, confidentiality-assured self-triage tool, Apollo 24|7 positioned itself as a safe first point of contact, ahead of (rather than a replacement for) in-person care reinforcing rather than cannibalizing the referral pipeline into its physical hospital network.

Media & Channel Strategy

Verified public information on Apollo 24|7’s media and channel strategy is limited primarily to distribution partnerships and platform infrastructure rather than disclosed advertising spend or campaign-level media plans. The documented channel strategy includes direct app and web distribution, the embedded partnership with Airtel Thanks to extend reach through an existing large-scale consumer app, and integration with Apollo’s own physical network pharmacy stores and hospitals as a channel for driving awareness and cross-referral into the digital platform.

Business & Brand Outcomes

Documented financial outcomes for Apollo 24|7 are available primarily through Apollo Hospitals Enterprise Limited’s corporate disclosures and subsequent reporting on Apollo HealthCo, the entity housing the digital and pharmacy businesses.

For the quarter ended June 2025 (Q1 FY26), Apollo HealthCo reported revenue of Rs 2,472 crore, up 19% year on year, with adjusted EBITDA of Rs 93.8 crore (a 3.8% margin) and a net profit of Rs 57.1 crore, compared with a net loss of Rs 12.9 crore in the corresponding quarter a year earlier. Within this, Apollo 24|7 specifically recorded a gross merchandise value of Rs 682.5 crore for the quarter, up 23% year on year, with the platform averaging approximately 57,000 daily orders and 13,000 daily consultations. For the full fiscal year 2025, Apollo HealthCo’s revenue stood at Rs 8,503 crore, up 14.7% from Rs 7,410 crore in the prior year, with EBITDA before the impact of accounting standard Ind AS 116 at Rs 252 crore, an increase of 60.5% year on year. As of FY25 reporting, 5,739 physical Apollo pharmacies had been integrated with the Apollo 24|7 digital platform, reflecting the omnichannel architecture underpinning the business.

The corporate actions around Apollo 24|7 the Rs 2,475 crore investment from Advent International in 2024 and the subsequent board-approved plan to demerge the pharmacy and digital health business into a separately listed entity represent the most consequential documented business outcomes of the platform’s build-out: external institutional capital validating the standalone value of the digital health business, and a structural decision by Apollo’s board to separate it from the hospital business ahead of a planned public listing.

Strategic Implications

Apollo 24|7 illustrates a distinct strategic path for incumbent healthcare providers responding to digital disruption: rather than treating digital as a bolt-on marketing channel, Apollo used its existing clinical and supply-chain assets as the structural foundation of a platform business, then sought external capital and eventual public-market validation for that platform as a distinct entity. The timing of the launch weeks before India’s COVID-19 outbreak intensified meant the platform’s early growth trajectory was shaped substantially by an exogenous public health crisis rather than by marketing execution alone, a reminder that platform adoption curves in healthcare can be driven as much by circumstance as by design.

The subsequent merger with Keimed and the investment from Advent International signal a second-order strategic insight: that building consumer-facing digital reach is, for an integrated player like Apollo, inseparable from strengthening the backend pharmaceutical distribution and supply chain that makes rapid delivery and consistent product availability possible. The planned demerger and separate listing of Apollo Healthtech further suggest that the market and Apollo’s own board increasingly view the digital health and pharmacy business as warranting a distinct valuation framework and investor base from the core hospital business, with its own growth, margin, and capital-intensity profile.

For other hospital groups and healthcare incumbents, the Apollo 24|7 case underscores that competing with asset-light digital health entrants does not necessarily require matching their venture-style growth tactics; it can instead involve converting existing clinical trust and physical infrastructure into a digital interface, while treating the digital business as a distinct strategic and eventually financial unit rather than a permanent extension of the core enterprise.

Discussion Questions

1. To what extent did Apollo 24|7’s early growth reflect a deliberate digital strategy versus a response to the exogenous shock of the COVID-19 pandemic, and what does this imply for how incumbents should plan digital transformation timelines?

2. How does Apollo’s approach of embedding existing physical assets (hospitals, pharmacies, doctor networks) into a digital platform differ strategically from the asset-light models of competitors such as Tata 1mg or PharmEasy, and what are the relative advantages and risks of each approach?

3. What does the Advent International investment and the subsequent decision to demerge the digital and pharmacy business into a separately listed entity (Apollo Healthtech) suggest about how capital markets value integrated versus standalone digital health businesses?

4. Given the merger with Keimed, a wholesale pharmaceutical distributor, how important is backend supply-chain integration to the success of a consumer-facing digital health platform, relative to front-end user experience and marketing?

5. In the absence of publicly disclosed user engagement metrics (such as MAU, retention, or CAC), what alternative indicators drawing only on the financial and structural data available would you use to assess whether Apollo 24|7 has succeeded in shifting healthcare discovery toward a digital-first model?